¿Son todos los test genómicos iguales?

16 / 43

1 )
“Tratamiento médico del cáncer en el año 2019”
Organiza:
6 , 7 y 8 d e f e b r e r o 2 0 1 9
NH Collection Eurobuilding
M A D R I D
C O O R D I N A D O R E S C I E N T Í F I C O S :
Eduardo Díaz-Rubio
Enrique Aranda Aguilar
Enrique Grande Pulido
Ana Lluch Hernández
Pedro Pérez Segura
Mariano Provencio Pulla
¿Son todos los test genómicos iguales?
Endorsed in 2013 St. Gallen Guidelines 1
Endocrine therapy alone Luminal A
Luminal B
Cytotoxics + anti-HER2
Could include anthracyclines and taxanes
HER2
enriched
Cytotoxic therapy alone, potentially including
anthracyclines, taxanes, and alkylating agent
Do not routinely use cisplatin or carboplatin
Basal-like
Comprehensive molecular portraits of breast cancer. Nature. 2012 Oct 4;490(7418):61-70
(1) Strategies for subtypes—dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
Annals of Oncology. Advance Access published on line June 27, 2011
PAM50-based intrinsic subtyping has been
independently validated by TCGA and
published in Nature in September 2012
Independently Validated
If HER2-, endocrine +/- cytotoxic therapy
If HER2+, cytotoxics + anti-HER2 + endocrine
Could include anthracyclines and taxanes